



**HAL**  
open science

# Evidence for link between mental disorders and in utero exposure to synthetic hormones: A long and crucial history

Marie-Odile Soyer-Gobillard, Laura Gaspari, Charles Sultan

## ► To cite this version:

Marie-Odile Soyer-Gobillard, Laura Gaspari, Charles Sultan. Evidence for link between mental disorders and in utero exposure to synthetic hormones: A long and crucial history. Mental Disorders [Working Title], IntechOpen, 2018, 10.5772/intechopen.80969 . hal-02335961

**HAL Id: hal-02335961**

**<https://hal.sorbonne-universite.fr/hal-02335961>**

Submitted on 28 Oct 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Evidence for link between mental disorders and *in utero* exposure to synthetic hormones: A long and crucial history.

---

Marie-Odile Soyer-Gobillard, Laura Gaspari and Charles Sultan

Additional information is available at the end of the chapter

## Abstract

The prenatal brain develops under the influence of the endogenous hormonal milieu (fetal, gonadal, adrenal, placental, maternal) and exogenous substances with hormonal activity. Somatic effects of diethylstilbestrol (DES) (genital malformations, infertility, cancers) on children exposed *in utero* have long been recognized. This is not the case for psychiatric disorders. Animal studies provide persuasive evidence of somatic and behavioral disorders.

Recent studies have reported psychiatric effects of synthetic estrogens on the brains of children exposed *in utero*, including mental disorders affecting the exposed children (psychotic disorders, schizophrenia, bipolar disorders, depression, eating disorders, suicides and suicide attempts), and have shown the epigenetic mechanism of the DES effect– a specific methylation of two genes playing important rôles in neuro-development: the ADAM TS9 and the ZFP 57 genes. The ADAM TS9 gene is involved in the control of the form of reproductive organs during development, the development of certain cancers; and (crucially) in controlling the development of the Central Nervous System ; methylation of ZFP 57 gene (located on chromosome 6), that is expressed very early in development as a transcription regulator, is highly suggesting to be associated with psychosis.

Progestins used in contraception and in hormone replacement therapy during menopause are known to affect the adult brain but no data on children existed before our recent paper on their effects after *in utero* exposure. Clinical data were collected from 1,200 families (1,934 children) of the HHORAGES cohort using a detailed medical questionnaire. Most families had children exposed to estrogens with or without progestin but 46 mothers (115 children) had at least one child exposed to only progestin. Our data show the presence of somatic disorders and a drastic increase of psychiatric disorders among children *in utero* exposed to progestin(s) (79,03 % vs 0% in unexposed first born and in children born after a previous maternal exposure). This result strongly suggests that synthetic progestin treatment during pregnancy may be detrimental for the development of children's brains. Mental disorders linked with *in utero* exposure to synthetic progestins are the same as pathologies provoked by *in utero* exposure to synthetic estrogens.

**Key words :** Synthetic estrogens, diethylstilbestrol, ethinylestradiol, synthetic progestins, mental disorders, *in utero* exposure.

**Short title:** Evidence for mental disorders in children exposed *in utero* to synthetic hormones (estrogens and/or progestins). Study of the french HHORAGES cohort.

### **Introduction.**

At the end of the 1990s, somewhere in France, an agricultural engineer, Mr. R.A. made the observation that his three children were suffering from various psychic and somatic pathologies, the elder suffering from bilateral cryptorchidism, micropenis, infertility due to azoospermia (no spermatozoa) and schizotypal character, the second of anxiety, depression and eating disorders (anorexia) coupled with small uterus and ovaries, and the third suffering from schizophrenia and severe depression associated with suicide attempts. He observed also the relationship with the fact that in all three cases his wife received medical treatment consisting of a synthetic hormone cocktail : Diethylstilbestrol (DES), Ethinyl Estradiol (EE), plus synthetic progestin delay during her three pregnancies after a previous miscarriage. He conducted research in the world literature on the subject, and came to the conclusion that not only was one of these products, Diethylstilbestrol (DES) already known for its misdeeds, but that it continued to be administered in France until 1977/82 : the product, inexpensive to make, was not patented and was manufactured and distributed by many pharmaceutical laboratories. The same goes for EE, which was banned for pregnant women in 1980, but remains the best-selling estrogen in the world because it is part of the contraceptive pill.

In 1998, one of us (MOS-G), concerned by the same kind of problems in her two children who were exposed *in utero* to the same cocktail of synthetic estrogens, lost her two children after psychiatric illnesses. Following the reading of a "Call to Families" printed in a newspaper, she met Mr. R. A., who had gathered around him about twenty French families concerned with their *in utero* exposed children suffering from psychiatric illnesses. He wanted to expose his observations and the results of his bibliographic researches at a meeting of patient families collecting observations on the genital malformations of girls exposed *in utero* to DES. Alas, he was condemned, rejected and disclaimed by doctors, mostly gynaecologists and psychiatrists as well as by associative members. They denied the existence of psychiatric disorders in exposed boys and girls. Discouraged, Mr R.A. died shortly afterwards. In order to continue his work and regroup the families concerned by the origin of the heavy psychiatric pathologies of their children, and despite the taboo surrounding such diseases as psychoses, we gathered several mothers concerned and

created the Association of Patients Histoires (Halt to Artificial Hormones for Pregnancies), in 2002. This Association which collected more than 1300 French spontaneous testimonies is now registered with the Epidemiology Portal of INSERM (French National Institute for Medical Research) as a French Health Database.

Despite various alerts published in the 1940s, after work on animals proving in particular its carcinogenic effect, and despite the work of Dieckmann et al. [1], initiated as early as 1953, demonstrating in a large cohort of pregnant women given Diethylstilbesterol (DES), a synthetic estrogen, *versus placebo* that the drug was inefficient in preventing miscarriages or premature births, this product has been widely distributed around the world, sowing a long list of misdeeds. After the discovery of cervico-vaginal cancers called "Clear Cells Adenoma (CCAD)"[2] in the "DES girls", DES was banned in the United States for pregnant women in 1971 but only in 1977 in France, where this recommendation disappeared from the "French Vidal book", but DES continued to be prescribed sporadically until 1982. Meanwhile another synthetic estrogen, steroidal, also synthesized on 1938, 17-alpha-ethinyl estradiol (EE) was often added to DES as a cocktail or later as a replacement, sometimes with the addition of synthetic-delay progestin. The idea that prevailed at the time was that women had a hormonal deficit that triggered a miscarriage, whereas now we know that the miscarriage itself causes this deficiency. These products were prescribed not only to women who had miscarriages, but also in comfort (« to have beautiful babies », according to an advertising), or even as a "morning after pill" or to cut milk after childbirth. DES and 17-alpha-EE, although belonging to different estrogenic and degrading categories, are, however, bound to the same ER beta-estrogen receptors.

### **Behavioral disorders demonstrated in animals (rats) exposed *in utero* [3-8].**

Animal studies (on mice and rats) have, demonstrated the toxicity of these synthetic estrogens on the offspring, including the causing of behavioral disorders. Palanza et al. [3] demonstrated in particular that prenatal exposure to three different synthetic chemicals, DES and two pesticides, DDT and methoxychlor its analogue, affects the behavior of young suckling mice, showing increased aggression in males (increased numbers of attacks and decreased reaction time before the attack (Fig. 1). Doses of DES were 1000 times less than those of DDT, and caused much larger aggression responses, demonstrating the considerable effect of DES at very low doses. The treatment period for rodent mothers from day 11 to day 17 of pregnancy was also critical because it represents a key period in the differentiation of the reproductive system and brain development in these rodents in the early stages of pregnancy.




Figure 1. Measurement of aggressiveness in young male mice after prenatal exposure to Diethylstilbestrol (DES) (0.02 and 0.2  $\mu\text{g} / \text{kg}$  [in gray], DDT [20 and 200  $\mu\text{g} / \text{kg}$ ] [in black], with a control without DES [in white]. There is an increase in the number of attacks and a decrease of the reaction time before the attack although the doses of DES are 1000 times less than those of DDT. According to Palanza et al. [3], with the permission of Elsevier (License No : 2514671323242).

Moreover, injection of 17-alpha- Estradiol (EE) in pregnant rats causes not only many abortions in mothers but also anxiety and depression disorders in offspring [4, 5], the synthetic hormone having been administered at the same relative doses as in humans (15 g / kg-1 per day *versus* 19 g / kg-1 per day). At the cytological level of the brain, an alteration of the anterior part of the hippocampus in young rats exposed to EE *in utero* has been demonstrated in 2004 [6]. The hippocampus is indeed a part of the brain that contains many estrogen receptors during the prenatal period. Ogiuekeda *et al* (7) showed on 2008 that synaptic plasticity can be upset by estrogens or other Endocrine Disruptors (EDs). Later and unequivocally, Newbold demonstrated the validity of the rodent model transposed to humans [8].

### **Behavioral disorders, psychoses and depressions demonstrated in humans after *in utero* exposure to DES / EE.**

In humans, the work concerning the appearance of behavioral disorders in children after *in utero* exposure to synthetic hormones is less numerous, but as early as 1977, June Reinisch (9) published in Nature that prenatal exposure to estrogen and / or synthetic progestins could affect the personality of exposed children. More recently, in 2012, Kebir and Krebs (10) have analyzed several epidemiological studies concerning the effects of DES on exposed children *in utero* and the

occurrence of psychiatric disorders in these children. Their analysis shows that only three large epidemiological studies on the effects of DES were performed in 1952-53 (followed-up in 1983); in 2007 and in 2010. The first study (double-blinded) that supports the hypothesis of a link between psychiatric disorders and prenatal exposure to DES was performed by Vessey *et al.*, in 1983 (11) from a clinical trial that had been performed thirty years earlier in 1953 in London by Dieckmann *et al.*, on 700 women treated with DES versus 700 subjected to a placebo (1). A doubling of depression and anxiety disorders has been demonstrated in the population exposed *in utero*. The second, published in 2007, and conducted by Verdoux *et al.* (12) from a cohort of women from the Mutuelle (Health) de l'Education Nationale (MGEN) concludes that there are no significant links between exposure to DES, suicides and / or psychiatric consultations or hospitalizations. A detailed analysis later, however, revealed a number of biases in this study (13). The most recent Nurses Health Study was conducted by O'Reilly *et al.* 2010 (14) from 76,240 American women among whom 1,612 women were exposed to DES *in utero*. The statistical analysis shows that the later experienced an increase in depressive and anxiety disorders by a factor of 1.3. Kebir and Krebs (10) emphasized the limitations of such epidemiological studies and noted in particular that, apart from depression and anxiety, other psychiatric disorders have not been studied. Post-adolescent behavioral disturbances reported for these two estrogens in exposed children were depression [15, 16], anxiety [1, 11, 17], schizophrenia-like [18, 19], anorexia, and bulimia nervosa [20]. All these observations were synthesized by Pillard *et al.* [16] and Giusti [21]. On 1987, Katz *et al.* [18] described the case of four male adults prenatally exposed to DES. It is in late adolescence that they develop psychotic disorders requiring neuroleptic treatment even though they have no family history of this type. He then hypothesizes that there may be a causal relationship between disruptions in neurodevelopment related to DES and the subsequent onset of psychotic disorders. Pillard *et al.* [16] showed that the frequency of recurrent major depressive episodes is significantly higher in the DES-exposed than in their unexposed siblings, which was confirmed in 2010 in the large cohort of DES girls by O'Reilly *et al.* [14].

Investigation of the causal link between exposure to these synthetic hormones *in utero* and severe psychotic disorders such as schizophrenia, bipolar disorders with or without eating disorders, schizoaffective disorders, occurring in post-adolescence in exposed children, was made possible thanks to the families of the Association Hhorages. Our database, constituted by these spontaneous families' testimonies, is based on responses to a detailed questionnaire, written by doctors and researchers, and accepted by the CNIL (French Center for the Protection of Data processing and Freedom). Our first global analysis (2004-2005 data) was based on 967 pregnancies from 470 mothers in collaboration with one of us (C.S.). The first results as well as the family questionnaires were detailed in 2012 in the chapter published in 2012 by Intech "Behavioral and somatic disorders in children exposed *in utero* to Synthetic Hormones" (13) in

which we detailed somatic and psychiatric disorders, associated or not, in the exposed children of our cohort.

We have conducted a more recent analysis (2016) (22, 23) based on 1182 pregnancies from 529 mothers (Figure 2).




Figure 2. Total number of psychological/psychiatric disorders among the 982 (1002 total with -20 stillborns) DES-exposed and post-DES unexposed children. First born children (intrafamilial control) unexposed are not ill.

Among the 740 (-20 stillborn) exposed children, 603 (exposed) +16 post-DES, (born without exposure but after a previous exposed pregnancy) are suffering from psychiatric disorders. The prevalence of the psychiatric disorders in comparison with the general population show a dramatic increase (Table 1).

	Group 1	Group 2	Group 3	
	First born pre-DES	DES-exposed	Post-DES	General population
	n= 180	n=740-20	n=262	
Behavioral disorders,	0%	n=109 (15,1%)	n=1 (0,4%)	3%
Schizophrenia :	0%	n=165 (22,9%)	n=6 (2,3%)	1%
Eating disorders :	0%	n=81 (11,3%)	n=2 (0,8%)	1,6%
Depression,				
bipolar disorders, anxiety :	0%	n=248 (34,4%)	n=9 (3,4%)	6,3%
Suicides : Attempts :	0%	n=612 (85%)	n=30 (11,5%)	0,3%
Death :	0%	n=32 (4,4%)	n=1 (0,4%)	0,02%

Table 1.

Prevalences of the psychological and/or psychiatric disorders in *in utero* exposed children to DES and/or EE and comparison with the general population (23).

We were also interested by the effects on the brain of synthetic progestins on *in utero*-exposed children of our cohort (Figures 3, 4). Currently, there is no research on ~~this~~ these effects of *in utero* exposure of children to progestins given alone during pregnancy. Our recent observations (24, 25) were collected from 1200 families of the Hhorages cohort i.e.1934 children using always the same detailed questionnaire (13). As previously shown, most families of our cohort had children exposed to estrogens or to estro-progestins, but only 46 families (115 children) had at least one child exposed to one or more progestins prescribed alone and representing 62 *in utero*-exposed children. 35 children were post-exposed (Figure 3). The prescribed progestins were : 17  $\alpha$  hydroxyprogesterone caproate (Synthetic Progestin, SP) against total indication in 2000 but re-authorized in 2011, - 17  $\alpha$  hydroxyprogesterone heptanoate (SP) : against total

indication in 2002, - chlormadinone acetate (SP), derived from hydroxyprogesterone, against total indication on 1970.




Figure 3. Total HHORAGES cohort of 1934 children in which three groups can be observed.

Among the 62 exposed children (22 girls + 40 boys), 49 presented psychiatric disorders, 6 somatic disorders only and 7 did not present any disorder. Only 1 post-exposed presented psychiatric disorder while 34 other post-exposed did not present any disorder.





Figure 4. Division of the 115 children of the 46 « Progestins » families : first born unexposed, *in utero* exposed, post exposed i.a. born after a previous exposed pregnancy.

Among the 49 children affected by psychiatric disorders, 3 boys and 7 girls presented both somatic disorders in addition to psychiatric ones: - Boys (3): Hypospad (1), No urinary meatus (1), Bilateral cryptorchidia + sexual ambiguity (1); - Girls (7): Hormonal sterility (2), Hirsutism + enuresia (1), Enuresia (1), Hirsutism (1), Hermaphrodism (1, operated), Sexual ambiguity + Tight urethra (1). Among the 6 exposed children suffering from somatic disorders “only” we observed for boys (4): Mega bilateral ureter (1 grand-child), Unilateral cryptorchidia (1), Hypospadias with numerous interventions of reconstruction (1 grand-child), Sexual ambiguity (1); for girls (2): Hormonal sterility (2).


As shown in Figure 5, a comparison of synthetic estrogen and progestin exposures for girls and boys demonstrates that psychiatric disorders were of the same nature for progestin exposure as those observed after exposure to synthetic estrogens i.a. Behavioral disorders= 2, Eating disorders= 2, Schizophrenia= 29, Depression, bipolar disorders= 16, Suicides : Attempts : 7 series, Death : 1. The percentage of suicide attempts (11,29%) and death

after suicide (1,6%) is proportionately lower after exposure to progestins than after exposure to synthetic estrogens.


a.



b.



c.



d.




Figure 5. Comparative diagrams representing psychiatric disorder cases presented respectively by girls (a, c) and boys (b, d) exposed either to synthetic estrogens DES, Diethylstilbestrol, EE, Ethinyl estradiol, (c, d) or to synthetic progestins (a, b).

### **An epigenetic mechanism.**

Search for the molecular basis of the causal link between *in utero*-exposure to synthetic hormones and the appearance of psychoses as schizophrenia or bipolar disorder in children exposed in utero, has been achieved thanks to the partnership that unites Hhorages Patients' Association with the Inserm team of molecular psychiatrist Pr. M.-O. Krebs (St Anne Hospital, Paris, France, UMR S 894), which began in 2007. "It would have been" crazy "to miss the problem posed by the Association Hhorages to establish a causal link between taking artificial hormone (s) during pregnancy and appearance of psychiatric disorders of the type psychotic in exposed children, because diethylstilbestrol (Distilbene® or DES) has been given over a limited period of time and people who have taken this molecule are still there to testify. This is a case study that should not be missed " said Dr. Kebir (Center for Psychiatry and Neuroscience, UMR S 894), manager of these researches as part of the Krebs' team.

First, to document *in utero* exposure to synthetic estrogens Kebir and Krebs (10) were able to analyze from our data a small number of family records that occurred in Hhorages testimonies, and studied a cohort of 472 exposed subjects. They account for 46.7% of mood disorders, 22.9% of psychotic disorders, 6.6% of anxiety disorders, 11% of eating disorders and 12.7% of others, which confirms their previous observations published on 2009 and 2010 at the 7th & 8th Congresses of the Encephalon in Paris (26, 27) on 43 exposed children highlighting clinical pictures with atypical associations.

Second, genetic and epigenetic analyzes of Hhorages siblings have shown in patients suffering from psychotic disorders and exposed in utero to DES and / or EE that this prenatal exposure is associated with epigenetic processes. Starting from the fact that psychiatric diseases develop from a brain dysfunction during neuro development, and knowing that DES and EE are synthetic hormones (estrogens), endocrine disruptors, and confirming from the Hhorages data numerous cases of heavy psychiatric disorders in children exposed, the Krebs'team in association with Hhorages, designed ten years ago, in 2007, a research project PICRI (Partnership Citizen Institution for Research and Innovation), funded by the Ile de France Region, net by the French National REsearch Agency (A.N.R.), that developed the hypothesis that the DES administered during pregnancies could be an environmental risk factor for the development of psychiatric disorders in impregnated children : the epigenome of the foetus could have been modified by *in utero* exposure to synthetic estrogens. The PICRI project was titled: "Influence of hormonal treatments on brain development during pregnancy: study of phenotypic, behavioral and biological changes in informative families". The families of Hhorages were called to perform peripheral blood sampling after thorough questioning. Many families volunteered to participate in the research: 31 families were selected, satisfying the rigorous inclusion criteria desired. Many more families had

come forward during this study, but they could not be included because the psychotic patient refused to come to St. Anne's Hospital for blood sampling. In the selected families total siblings were composed of first born unexposed children, exposed and post exposed children, with first born unexposed serving as intrafamilial control. For the exploration of their epigenome, 485,000 cytosines by genome were studied and analysed, representing an immense work. To complete this study, a cohort of young adolescents with relational, emotional and social difficulties was followed for six months, some of whom had developed schizophrenic-type psychosis in these six months, although not exposed to DES. A comparison of their methylome, analyzed before and after the onset of the disease was performed. In this study (28), authors reported a global methylation of the psychotic patient genome.

After the analysis of the whole methylome of the selected Hhorages cohort, the team of Krebs-Kebir highlighted differential specific methylated regions (DMR) : in the zinc finger protein 57 gene ZFP57 and in the ADAM TS9 gene, in young psychotic patients exposed in utero to DES/EE (29, 30). In this work, the authors observed that in exposed individuals, ZFP57 gene methylation may be associated with their psychosis. The ZFP57 gene (located on chromosome 6), is expressed very early in development. It is a transcription regulator, directly related to the phenomenon of methylation and neurodevelopment (31). The ADAM TS9 gene is implicated in the control of organ shape, especially in the development and function of the uterus and reproductive organs (32) which are often abnormal after *in utero* DES exposure as well as in the control of the CNS development (33) and in several kinds of cancers (34).

## **Discussion and conclusion**

Very few studies have investigated the impact of prenatal exposure to DES, EE on psychiatric outcome. Animal studies on rats or mice allowed us to hypothesize that estrogenic hormones induce neurodevelopmental disturbances in exposed human subjects and may potentially mediate an increased risk of behavioral and psychiatric disorders. Our data therefore strongly suggest that DES/EE exposure during pregnancy is associated with high incidence of behavioral and/or psychiatric disorders. They illustrate a higher risk of schizophrenia, as this disease was 17 times more prevalent than in the general population, with sons being more affected than DES daughters. Regarding the existence of eating disorders (bulimia, anorexia), it should be noted that girls are much more affected than boys, and we often observed the association of eating disorders with bipolarity (manic-depressive disorders), anxiety and depression. With regard to suicides, our work clearly demonstrates a drastically increased risk of suicide attempts (65.4% versus 0 in the unexposed controls and 0.25% in general population) and suicides (3.4% versus 0 in the unexposed controls and 0.02% in general population). It could be noted that, as in the general population, DES sons commit more suicides than DES daughters, and the inverse for suicide attempts. Moreover, our data reveal that 50% of the sons who committed suicide suffered from schizophrenia. Psychiatric studies in general have shown that

the percentage of suicides is generally higher in individuals with psychiatric disorders than in the general population. But to our knowledge, there is no information or specific studies concerning this association in the context of DES exposure. Sixteen subjects in Group 3 (post-DES children) (Figure 2, Table 1) had diagnosed psychiatric disorders. An explanation for this finding might be that DES, being a very lipophilic synthetic estrogen, remains in the mothers' fat after estrogenic impregnation in a previous pregnancy and is then released through the placental barrier during the next gestation.

No work had been reported on the impact of *in utero* exposure to synthetic progestin hormones administered alone on the occurrence of psychiatric disorders in exposed children before our first presentation in the European Congress of Gynaecology in 2017 (24). For the first time we described psychiatric disorders that can affect children exposed *in utero* to progestins. Previously, and during many years, synthetic progestogens were not considered as dangerous during pregnancy or during replacement or contraceptive treatment. Moreover, they have been suggested to exert neuroprotective effects in several animal models of neurological disease (35). Negative mood symptoms have been reported by Andreen et al. (36) in some women as a result of progesterone during the luteal phase of menstrual cycles. This is believed to be mediated via the action of allopregnenolone on the GABA-A system. A reduction of allopregnanolone circulating levels that correlates to depressive symptoms has been recently reported (37) and conversely, healthy women reported increased anxiety and mood disorders after long-acting subdermal implant of progestogens. In a group of 236 schizophrenic patients at onset, an elevated concentration of progesterone has been found, and authors suggested that steroid hormones may influence brain function, underlying schizophrenia and major depressive disorders (38). Moreover, Buoli et al (2016) found high DHAS levels in patients with a history of psychotic symptoms, suggesting a role of steroids in the aetiology of psychosis and mood disorders (39). Progestins are known to induce GABA receptor activity/neural activation before birth, it is likely that GABAergic system could contribute to schizophrenia, anxiety, depression, panic disorders, epilepsy, autism and others (40). Although some progestins have been banned from the market, others are not: our data demonstrated that caution should be taken with regard to the use of these progestins during pregnancy and even outside these periods (contraception or hormone replacement therapy).

The brain is a very vulnerable organ because its development covers a very broad period extending from the early prenatal stage (3rd week of pregnancy) to end around the age of 20. During its development, there are times when its vulnerability is even greater than others; these periods are called "shooting windows", during which the environment can impact the normal process of development. Abdomaleky et al (41) as early as 2005 had developed the hypothesis that gene-environment modulations could be performed via DNA methylations. The Krebs' team

put forward the hypothesis that DES-induced changes in epigenetic background and alteration of DNA functioning (methylations) could be significant factors to demonstrate a possible origin of psychotic disorders and a link with *in utero* DES exposure of the children suffering from these illnesses (29, 30).

Numerous studies have shown that, for example in the rat, early maternal separation or the fact of causing significant stress to the mother changes the methylation signals of certain genes of the rat directly related to the regulation of anxiety. It has also been discovered that the proper environment for changing the methylation signals may be chemical. This is the case of DES recognized by the scientific community as an endocrine disruptor, and banned for pregnant women. This change in level of methylation caused *in utero* by DES has been demonstrated for uro-genital malformations of girls and boys as well as for cancers. On 2015, Harlid et al. published in a pioneer work the first study for evaluation of possible effects of *in utero* DES exposure on genome-wide DNA methylation in humans (42). They studied whole blood DNA methylation in one hundred 40–59 years old women reporting *in utero* exposure, compared to 100 unexposed women. They did not find any differential methylation, but the DMR approach was not used in their recent work (2015). On the other hand, in 2017 Rivollier et al. (30) described specific Differential Methylated Regions (DMR) on two genes implicated in neurodevelopment (ZFP57 and ADAMTS9). Surprisingly, they cautiously claim that these DMR are « supposedly » associated with prenatal exposure to DES in young psychotic patients *in utero* exposed to DES/EE. Nevertheless, these modifications of methylation are really specific because they do not exist in the methylome of young psychotic patients not exposed to DES (28) in which global methylation of the genome was observed. Moreover authors have compared exposed subjects to their unexposed siblings which do not present these specific methylations although they shared environmental and genetic factors.

In conclusion, the citizen work carried out between the French Hhorages Patient Association and two major medical research laboratories has provided convincing scientific results 1- on the detection and confirmation of the existence of psychiatric disorders (accompanied or not of somatic disorders) in children exposed *in utero* to synthetic hormones, 2- on the mechanisms of action of these synthetic hormones administered to pregnant mothers on the brain of their offspring. The effects of these endocrine disruptors in humans through what is becoming a public health scandal, denied for a long time by doctors, especially psychiatrists, scientists and specialized journalists are thus better known. The fact that these synthetic products do not degrade in the human body in the same way as the natural hormones (13), and act on the functioning of genes implicated in neurodevelopment during the foetal life, following an epigenetic mechanism, is a real time bomb. Indeed, this mechanism induces a transgenerational effect already partially demonstrated in the Hhorages cohort at the 3rd generation level for hypospadias, a specific genital malformation. So far, only a few third-generation children suffering psychiatric illness are

documented in the Hhorages testimonies. This is understandable because third generation exposed children are still too young (excepted in some cases) to present psychiatric disorders as schizophrenia which is not the case for hypospads that are detectable from birth in male children and grand-children (43). In contrast, psychiatric disorders usually appear in post-adolescence, 18-20 years, and sometimes later.

## Disclaimer

The authors declare they have no competitive financial interests; the financing of HHORAGES-France association comes exclusively from the donations of families and of sympathetic individuals.

## Acknowledgements.

Mr René Alexandre, Dr Henri Pézerat, Pfr Jean Caston, Mr Michel Datry, Dr Charles Zelwer worked tirelessly to demonstrate the harmful role of the endocrine disruptors, and in particular of synthetic hormones, before passing away: we shall never forget their efficient help. This work could not continue without the daily ongoing support of the HHORAGES board especially Mrs Geneviève A., Mauricette P., Yette B., Annie R., Aimée I., Sylvette C., Denise H., Marie-Noëlle P. and Pierre D. We acknowledge Mr André Cicoella, President of the French Environment-Health network (RES) for his constant support. We are very grateful to Pfr Michael Dolan, Professor at the University of Massachusetts, Amherst (USA) for his help and critical reading during the preparation of the manuscript.

## References

- [1] Dieckman WJ, Davis ME, Rynkiewicz LM, Pottinger RE (1953) Does the administration of diethylstilbestrol during pregnancy have therapeutic value? *American Journal of Obstetrics and Gynaecology* 66: 1062-1081.
- [2] Herbst AL, Ulfelder H, Poskanzer DC (1971) Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. *New England Journal of Medicine* 284 (15): 878-881.
- [3] Palanza P, Morellini F, Parmigiani S, Vom Saal FS (1999) Prenatal exposure to endocrine disrupting chemicals: effects on behavioral development. *Neurosci Biobehav Rev* 23, 1011—1027.
- [4] Dugard ML, Tremblay-Leveau H, Mellier D, Caston J (2001) Prenatal exposure to ethinylestradiol elicits behavioural abnormalities in the rat. *Developmental Brain Research* 129: 189-199.
- [5] Arabo A, Lefebvre M, Fermanel M, Caston J (2005) Administration of 17-alphaethinylestradiol during pregnancy elicits modifications of maternal behaviour and emotional alteration of the offspring in the rat. *Developmental Brain Research* 156: 93- 103.
- [6] Sandner G, Barbosa Silva MJ, Angst J, Knobloch JM, Danion JM (2004) Prenatal exposure of Long-Evans rats to 17alpha-ethinylestradiol modifies neither latent inhibition nor prepulse inhibition of the startle reflex but elicits minor deficiency in exploratory behaviour. *Developmental Brain Research* 152: 177-187.
- [7] Ogjie-Ikeda M, Tanabe N, Mukai H, Hojo Y, Murakami G, Tsurugizawa T, et al. (2008) Rapid modulation of synaptic plasticity by estrogens as well as endocrine disruptors in hippocampal neurons. *Brain Res Rev. Mar*; 57(2):363–75. <https://doi.org/10.1016/j.brainresrev.2007.06.010> PMID: 17822775
- [8] Newbold RR (2004) Lessons learned from perinatal exposure to diethylstilbestrol. *Toxicology and Applied Pharmacology* 199: 142-150.
- [9] Reinisch JM (1977) Prenatal exposure of human fetuses to synthetic progestin and oestrogen affects personality. *Nature* 266: 561-562.
- [10] Kebir O, Krebs, MO (2012) Diethylstilbestrol and risk of psychiatric disorders: A critical review and new insights. *The World Journal of Biological Psychiatry*, 13 (2): 84-95.
- [11] Vessey MP, Faiweather DV, Norman-Smith B, Buckley J. (1983) A randomized double-blind controlled trial of the

- value of stilboestrol therapy in pregnancy: long term follow-up of mothers and their offspring. *Br J Obstet Gynecol* 90:1007-1017.
- [12] Verdoux H, Ropers J, Costagiola D, Clavel-Chapelon F, Paoletti X (2007) Serious psychiatric outcome of subjects prenatally exposed to diethylstilbestrol in the E3N cohort study. *Psychological Medicine* 37: 1315-1322.
- [13] Soyer-Gobillard MO, Sultan Ch (2012) Behavioral and Somatic Disorders in Children exposed *in utero* to Synthetic Hormones : a Testimony-Case Study in a French Family Troop, In: "State of the Art of Therapeutic Endocrinology", Editor Dr. Sameh Magdeldin, Niigata University, Japan. InTech, pp. 67-86.
- [14] O'Reilly EJ, Mirzaei F, Forman MR, Ascherio A. (2010) Diethylstilbestrolexposure in utero and depression in women. *Am J Epidemiol* 171: 876—82.
- [15] Ehrhardt AA, Feldman JF, Rosen LR, Meyer-Bahlburg R, Gruen NP, Veridiano NP, et al. (1987) Psychopathology in prenatally DES-exposed females: current and lifetime adjustment. *Psychosom Med* 49:183—96.
- [16] Pillard RC, Rosen H, Meyer-Bahlburg JD, Weinrich JF, Feldman JF, Gruen R, et al. (1993) Psychopathology and social functioning in men prenatally exposed to diethylstilbestrol (DES). *Psychosom Med* 55:485—91.
- [17] Saunders G (1988) Physical and psychological problems associated with exposure to diethylstilbestrol (DES). *Hosp Community Psychiatry* 39:73—7.
- [18] Katz DL, Frankenburg FR, Frances R, Benowitz LI, Gilbert JM. (1987) Psychosis and prenatal exposure to diethylstilbestrol. *J Nerv Ment Dis* 175:306—8.
- [19] Verdoux H (2000) Quelles sont les conséquences psychiatriques de l'exposition intra-utérine au diethylstilbestrol (DES)? *Ann Med Psychol* 158:105—17.
- [20] Geary N (1998) The effect of estrogen on appetite. *Medscape Women Health* 3(10.): 3.
- [21] Giusti RM, Iwamoto K, Hatch E (1995) Diethylstilbestrol revisited: A review of the long term health effects. *Annals of Internal Medicine* 122: 778-788.
- [22] Soyer-Gobillard MO, Paris F, Gaspari L, Courtet Ph, Sultan Ch (2016) Endocrine disruptors (ED) and psychiatric disorders in children exposed *in utero*: Evidence from a French cohort of 1002 prenatally exposed children and the example of diethylstilbestrol (DES) as a model for ED study. 2nd PARIS Workshop on Endocrine Disruptors: Effects on Wildlife and Human Health. Paris (Institut Pasteur), 21-22 Janvier 2016.
- [23] Soyer-Gobillard MO, Gaspari-Sultan L, Paris F, Courtet Ph, Sultan Ch (2016) Association between foetal DES-exposure and psychiatric disorders in adolescence/adulthood: evidence from a French cohort of 1002 prenatally exposed children. *Gynecological Endocrinology* 32 (1), 25-29. DOI : 10.3109/09513590.2015.1063604.
- [24] Soyer-Gobillard MO, Gaspari-Sultan L, Paris F, Courtet Ph, Sultan Ch (2017) Neurodevelopmental disorders in children exposed *in utero* to progestin treatment: study of a cohort of 95 children from the HHORAGES Association. 12è Congress of the European Society of Gynecology, Barcelona, 18-21 October 2017.
- [25] Soyer-Gobillard MO, Gaspari-Sultan L, Paris F, Courtet Ph, Puillandre M, Sultan Ch (2018) Neurodevelopmental disorders in children exposed *in utero* to synthetic Progestins: Analysis from the national cohort of the Hhorages Association. Just accepted by *Gynecological Endocrinology*. <https://doi.org/10.1080/09513590.2018.1512968>
- [26] Roblin J, Chayet M, Bon Saint Come M, Kebir O, Bannour S, Guedj F, Krebs M-O (2009) Troubles psychiatriques et exposition *in utero* aux hormones de synthèse: Etude d'une série de cas. 7<sup>ème</sup> Congrès de l'Encéphale, Paris, 22-24-01, PO 010.
- [27] Kebir O, Chayet M, Gorsane M-A, Ben Jemaa N, Krebs M-O (2010) Exposition durant la grossesse aux hormones de synthèse et augmentation du risque des troubles psychiatriques: revue critique. 8<sup>ème</sup> Congrès de l'Encéphale, Paris, 36 : 3-9. PO. 001.
- [28] Kebir O, Chaumette B, Rivollier F, Miozzo F, Lemieux Perreault LP, Barhdadi, A, Provost S, Plaze M, Bourgin, J, the Icaar team, Gaillard R, Mezger V, Dube MP, Krebs MO (2016) Methylomic changes during conversion to psychosis. *Molecular Psychiatry* 1—7.
- [29] Rivollier F, Kebir O, Chaumette B, Krebs MO (2016) Methylomic changes in individuals with psychosis and prenatally exposed to Diethylstilbestrol. Schizophrenia International Research Society Conference (2016), npj Schizophrenia 16009, PO S202.
- [30] Rivollier F, Chaumette B, Bendjemaa N, Chayet M, Millet B, Jaafari N, Barhdadi A, Lemieux Perreault LP, Provost

- S, Dube MP, Gaillard R, Krebs MO, Kebir O (2017) Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol. *PLoS ONE*, (2017) ; 12(4): e0174783. <https://doi.org/10.1371/journal.pone.0174783>
- [31] Quenneville S, Verde G, Corsinotti A, Kapopoulou A, Jakobsson J, Offner S, et al. In embryonic stem cells, ZFP57/KAP1 recognize a methylated hexanucleotide to affect chromatin and DNA methylation of imprinting control regions. *Mol Cell*. 2011 Nov 4; 44(3):361–72. <https://doi.org/10.1016/j.molcel.2011.08.032> PMID: 22055183
- [32] Mittaz L, Russell DL, Wilson T, Brasted M, Tkalcovic J, Salamonsen LA, et al. Adamts-1 is essential for the development and function of the urogenital system. *Biol Reprod*. 2004 Apr; 70(4):1096–105. <https://doi.org/10.1095/biolreprod.103.023911> PMID: 14668204
- [33] Lemarchant S, Pruvost M, Montaner J, Emery E, Vivien D, Kanninen K, et al. ADAMTS proteoglycanases in the physiological and pathological central nervous system. *J Neuroinflammation*. 2013; 10:133. <https://doi.org/10.1186/1742-2094-10-133> PMID: 24176075
- [34] Zhang C, Shao Y, Zhang W, Wu Q, Yang H, Zhong Q, et al. High-resolution melting analysis of ADAMTS9 methylation levels in gastric, colorectal, and pancreatic cancers. *Cancer Genet Cytogenet*. 2010 Jan 1; 196(1):38–44. <https://doi.org/10.1016/j.cancergencyto.2009.08.016> PMID: 19963134
- [35] Melcangi RC, Giatti S, Calabrese D, Pesaresi M, Cermenati G, Mitro N, Viviani B, Garcia-Segura LM, Caruso D. Levels and actions of progesterone and its metabolites in the nervous system during physiological and pathological conditions. *Progress in Neurobiology* 2014; 113 (2): 56-69.
- [36] Andreen L, Nyberg S, Turkmen S, van Wingen G, Fernandez G, Bäckström T. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. *Psychoneuroendocrinology*, 2009; 34: 1121-1132.
- [37] Slopian R, Pluchino N, Warenik -Szymankiewicz A, Sajdak S, Luisi M, Drakopoulos P, Genazzani AR. Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause. *Gynecological Endocrinology*, 2018 ; 34 (2) : 144-147.
- [38] Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren N (J.M.), Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. *Psychoneuroendocrinology*, 2011; 36 (7): 1092-1096.
- [39] Buoli M, Caldiroli A, Serati M, Grassi S, Altamura AC. Sex Steroids and Major Psychoses: Which Role for DHEA-S and Progesterone? *Neuropsychobiology*, 2016; 73: 178-183.
- [40] Schmidt MJ, Mirmics K. Neurodevelopment, GABA System dysfunction, and schizophrenia. *Neuropsychopharmacology Reviews*, 2014; 1-17.
- [41] Abdolmaleky HM, Smith, CL, Faraone SV, Shafa R, StoneW, Glatt, SJ and Tsuang MT (2004) Methylomics in psychiatry: modulation of gene–environment interactions may be through DNA methylation. *American Journal of Medicine Genetics B Neuropsychiatric Genetics*, 127, 51–59
- [42] Harlid S, Xu Z, Panduri V, D'Aloisio AA, DeRoo LA, Sandler DP, et al. In utero exposure to diethylstilbestrol and blood DNA methylation in women ages 40–59 years from the sister study. *PLoS One*. 2015; 10(3):e0118757. <https://doi.org/10.1371/journal.pone.0118757> PMID: 25751399
- [43] Kalfa N, Paris F, Soyler-Gobillard MO, Daures JP, Sultan Ch (2011) Incidence of hypospadias in grandsons of DES-exposed women during pregnancy: a multigenerational national cohort study. *Fertility and Sterility* 95 (8): 2574-2577.

## Author details

### Marie-Odile Soyer-Gobillard, PH.D.



*Emeritus Honorary Research Director at National Center for Scientific Research (CNRS), Sorbonne University, P. and M. Curie Univ. Paris 6. National President of HHORAGES Association (Halt to Artificial Hormones for Pregnancies), The Priory of Baillon, F-95270 Asnieres sur Oise, France.*  
[www.hhoragesfrance.com](http://www.hhoragesfrance.com)

*Doctor of Science (Cell Biology), Researcher, laureate of several scientific awards and author of more than 150 publications in peer-reviewed scientific journals and several invited reviews. Former Director of the Department of Cellular and Molecular Biology (UMR 796 « Models in Cell and Evolutive Biology ») at the Arago Laboratory (Paris 6 University). Vice-President of section 28 (Biology of Organisms and Development) of the National Committee C.N.R.S. during five years, Expert at the ANR (National Agency for Research) and President of Scientific Council of HHORAGES. Member of the Clinical Project Re-readers Committee at National Institute for Medical Research (INSERM), Paris.*

Email: [elido66@orange.fr](mailto:elido66@orange.fr)



**Charles Sultan, MD., PH.D.** *Emeritus Professor of Pediatric Endocrinology from the University of Montpellier, Unité d'endocrinologie et gynécologie pédiatrique, Hôpital Arnaud-de-Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France. He made a post-doctoral fellowship at the John Hopkins's Hospital (Baltimore, USA) at the Department of Pediatric Endocrinology. He was certified in biochemical genetics at the NIH, Betesda, MD. He chaired the Pediatric Endocrine Unit at the University Hospital of Montpellier, simultaneously an Inserm group in molecular genetics of androgens and disorders of sex differentiation. He published more than 500 publications and invited reviews. He won several international prizes in Pediatric Endocrinology.*

Email : [c-sultan@chu-montpellier.fr](mailto:c-sultan@chu-montpellier.fr)



**Laura Gaspari, MD.** *Unité d'endocrinologie et gynécologie pédiatrique, Hôpital Arnaud-de-Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France. She carried out a post-doctoral fellowship in Pediatric Endocrinology at the Unité d'Endocrinologie et Gynécologie Pédiatrique, département de Pédiatrie, CHU de Montpellier et Université de Montpellier (France) during 5 years, She is National post graduate in Pediatric Endocrinology and National post graduate in Pediatric and Adolescent Gynecology. She contributed to 30 publications in peers-reviewed journals and several invited reviews.*

Email : [dr.lauragaspari@gmail.com](mailto:dr.lauragaspari@gmail.com)